Ybrain Receives Translational Research Award 2022 Neuroergonomics Conference & NYC Neuromodulation Conference -- MEDICA - World Forum for Medicine

27/09/2022

Ybrain Inc.

Ybrain Receives Translational Research Award 2022 Neuroergonomics Conference & NYC Neuromodulation Conference

NEW YORK, Aug. 18, 2022 /PRNewswire/ -- Ybrain recently received the Translational Research Award at this year's Neuroergonomics Conference and NYC Neuromodulation Conference held from July 28 to August 1 for its neuromodulation technology in transcranial direct current stimulation (tDCS). 

The highly sought-after recognition was conferred to researchers who made a significant contribution to the neuromodulation field with only two out of dozens of renowned scholars of neuromodulation being awarded.

The conferences were joined together to address the state-of-the-art neurotechnology for brain-body performance and health. It focused on the latest approaches for both brain function and dysfunction including brain/body performance, depression, skill acquisition, stress and fatigue, pain, addiction and binge eating, cognition and physical recovery, eye-tracking, neuromarketing, and remote/mobile sensing. These themes were intended to encourage discussion that crossed traditional sub-domains of neurotechnology.
Ybrain's award-winning neuromodulation technology, tDCS, is designed for the treatment of major depressive disorder and tDCS caters to patients that wish to manage use of antidepressants as a form of treatment. tDCS is used in the company's MINDD-STIM+ treatment. This is especially relevant in today's post-pandemic world as COVID-19 resulted in a surge of new cases.

Exhibitor Data Sheet